Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 047-2009 |
Not provided
Not provided
Not provided
Study design required a change in device
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Johnson & Johnson | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a prospective, non-randomized, observational, multicentre (5 sites) study in which subjects that have surgically-correctable Stress Urinary Incontinence undergo a TVT SECUR operative procedure.
The study will collect preoperative urologic testing, medical history, and subject quality of life patient questionnaires, Intraoperative procedural data will be collected.
Postoperative complications, urologic, testing, and subject questionnaires will be collected at intervals up to 24 months. The anatomic position of the device will be characterize by transvaginal ultrasound testing.
To determine the rate and/or improvement rate of patients who have received the Gynecare Secur device after 12 months and after 24 months.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Gynecare TVT Secur | Procedure | Implant of the Gynecare TVT Secur |
| Measure | Description | Time Frame |
|---|---|---|
| The primary endpoints are the cure/improvement rate in the cohort at 12 months. | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Distribution of percentage of subjects having a decrease of pad weight as compared to baseline | 24 months | |
| Decrease in number of pads used within a 24-hour period as compared to baseline | 24 months |
Not provided
Inclusion Criteria:
To be considered eligible to participate in this study, subjects must meet the following requirements:
Exclusion Criteria:
Subjects will not be eligible for entry into the study if they meet one of the following criteria:
Not provided
Not provided
Approximately 125 women with SUI from 5 centres across Canada will participate in this study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sender Herschorn, MD | Sunnybrook Health Sciences Centre | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sunnybrook Health Sciences Centre | Toronto | Ontario | M4N 3M5 | Canada |
Not provided
| ID | Term |
|---|---|
| D014550 | Urinary Incontinence, Stress |
| ID | Term |
|---|---|
| D014549 | Urinary Incontinence |
| D014555 | Urination Disorders |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Change in patient questionnaires from baseline | 24 months |
| Change in the sling position on transvaginal ultrasound | 24 months |
| Cure/improvement rate at 24 months | 24 months |
| D005261 |
| Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D059411 | Lower Urinary Tract Symptoms |
| D020924 | Urological Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |